display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - adjuvantbreast cancer - HER2-positive
breast cancer - adjuvantla/mBC - HER2 positive - 1st Line (L1)
pertuzumab based treatment
pertuzumab plus trastuzumab APHINITY PERTAIN
pertuzumab plus trastuzumab plus docetaxel PUFFIN CLEOPATRA

Study type: